journal article·2025-03

Insights into Non‐Metallic Magnetic Resonance Imaging Contrast Agents: Advances and Perspectives

Yanan Wang, Xuehua Ma, Yunhao Zhang, Yanqiang Yang, Pengyu Wang, Tianxiang Chen, Changyong Gao, Chen Dong, Jianjun Zheng, Aiguo Wu

Small· Volume 21· Issue 10
Publisher page

Abstract

Abstract Traditional metal‐based magnetic resonance imaging contrast agents (MRI CAs), such as gadolinium, iron, and manganese, have made significant advancements in diagnosing major diseases. However, their potential toxicity due to long‐term accumulation in the brain and bones raises safety concerns. In contrast, non‐metallic MRI CAs, which can produce a nuclear magnetic resonance effect, show great promise in MRI applications due to their adaptable structure and function, good biocompatibility, and excellent biodegradability. Nevertheless, the development of non‐metallic MRI CAs is slow due to the inherent low magnetic sensitivity of organic compounds, their rapid metabolism, and susceptibility to reduction. Designing effective multifunctional organic compounds for high‐sensitivity MRI remains a challenge. In this discussion, the mechanisms of various non‐metallic MRI CAs are explored and an overview of their current status, highlighting both their advantages and potential drawbacks, is provided. The key strategies for creating high‐performance MRI CAs are summarized and how different synthetic approaches affect the performance of non‐metallic MRI Cas is evaluated. Last, the challenges and future prospects for these promising non‐metallic MRI CAs are addressed.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Lanthanide and Transition Metal Complexes · Advanced MRI Techniques and Applications · Radioactive element chemistry and processing

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Cixi Biomedical Research Institute Wenzhou Medical University Cixi 315300 China

Laboratory of Advanced Theranostic Materials and Technology Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology Chinese Academy of Sciences (CAS) Key Laboratory of Magnetic Materials and Devices Ningbo Institute of Materials Technology and Engineering Chinese Academy of Sciences Ningbo 315201 China

University of Chinese Academy of Sciences Beijing 100049 China

Department of Radiology Ningbo No.2 Hospital Ningbo 3l5010 China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Zhejiang Province · Natural Science Foundation of Ningbo Municipality

References (100+)

Show source-provided references
1. 10.1109/TMI.2007.90812110.1109/TMI.2007.908121 ↗
2. 10.1016/j.progpolymsci.2012.07.00110.1016/j.progpolymsci.2012.07.001 ↗
3. 10.1021/acs.chemrev.8b0036310.1021/acs.chemrev.8b00363 ↗
4. 10.1148/radiol.201514269010.1148/radiol.2015142690 ↗
5. 10.1002/alz.04165710.1002/alz.041657 ↗
6. 10.2215/CJN.0601110810.2215/CJN.06011108 ↗
7. 10.1016/j.biomaterials.2011.05.03510.1016/j.biomaterials.2011.05.035 ↗
8. 10.1016/j.progpolymsci.2020.10128610.1016/j.progpolymsci.2020.101286 ↗
9. 10.1002/advs.20200046710.1002/advs.202000467 ↗
10. 10.1097/00004424-198411000-0001410.1097/00004424-198411000-00014 ↗
11. 10.1021/acs.bioconjchem.9b0049910.1021/acs.bioconjchem.9b00499 ↗
12. 10.1006/jmre.1999.195610.1006/jmre.1999.1956 ↗
13. 10.1002/anie.20190472210.1002/anie.201904722 ↗
14. 10.1021/acssensors.1c0240810.1021/acssensors.1c02408 ↗
15. 10.1021/jacs.7b0829210.1021/jacs.7b08292 ↗
16. 10.1002/mrm.2828110.1002/mrm.28281 ↗
17. 10.3390/pharmaceutics1402045110.3390/pharmaceutics14020451 ↗
18. 10.1021/cr500286d10.1021/cr500286d ↗
19. 10.1038/125016a010.1038/125016a0 ↗
20. 10.7150/thno.2378910.7150/thno.23789 ↗
21. 10.1186/1532-429X-12-7110.1186/1532-429X-12-71 ↗
22. 10.1039/C4CS00345D10.1039/C4CS00345D ↗
23. 10.7150/thno.5700410.7150/thno.57004 ↗
24. 10.1103/PhysRev.73.67910.1103/PhysRev.73.679 ↗
25. 10.1021/acs.chemrev.5b0011210.1021/acs.chemrev.5b00112 ↗
26. 10.1039/c3cc44268c10.1039/c3cc44268c ↗
27. 10.1021/jacs.6b0813810.1021/jacs.6b08138 ↗
28. 10.1021/acs.jpcc.6b0173710.1021/acs.jpcc.6b01737 ↗
29. 10.1021/jacs.9b0055810.1021/jacs.9b00558 ↗
30. 10.1002/adom.20170064410.1002/adom.201700644 ↗
31. 10.1021/acs.nanolett.2c0232610.1021/acs.nanolett.2c02326 ↗
32. 10.1016/j.apmt.2019.10052410.1016/j.apmt.2019.100524 ↗
33. 10.1039/C4NR07591A10.1039/C4NR07591A ↗
34. 10.1021/acs.nanolett.6b0066410.1021/acs.nanolett.6b00664 ↗
35. 10.1016/j.biomaterials.2011.12.01810.1016/j.biomaterials.2011.12.018 ↗
36. 10.1038/ncomms646010.1038/ncomms6460 ↗
37. 10.3892/ijmm.2016.274410.3892/ijmm.2016.2744 ↗
38. 10.1002/adma.20190653910.1002/adma.201906539 ↗
39. 10.1021/acsomega.1c0707110.1021/acsomega.1c07071 ↗
40. 10.1021/acs.nanolett.3c0104410.1021/acs.nanolett.3c01044 ↗
41. 10.1021/jacs.1c0293810.1021/jacs.1c02938 ↗
42. 10.1039/D0CP06071B10.1039/D0CP06071B ↗
43. 10.1021/jacs.1c0737110.1021/jacs.1c07371 ↗
44. 10.1002/anie.20231733710.1002/anie.202317337 ↗
45. 10.3390/antiox1108145410.3390/antiox11081454 ↗
46. 10.2147/IJN.S37872610.2147/IJN.S378726 ↗
47. 10.3233/JAD-16027910.3233/JAD-160279 ↗
48. 10.1016/j.ccr.2018.02.00210.1016/j.ccr.2018.02.002 ↗
49. 10.1021/acsami.5b0399810.1021/acsami.5b03998 ↗
50. 10.1016/j.jconrel.2013.01.02910.1016/j.jconrel.2013.01.029 ↗
51. 10.1002/mrm.191005060310.1002/mrm.1910050603 ↗
52. 10.1016/j.ejca.2012.10.02610.1016/j.ejca.2012.10.026 ↗
53. 10.1002/chem.20170278510.1002/chem.201702785 ↗
54. 10.1021/acs.langmuir.7b0112610.1021/acs.langmuir.7b01126 ↗
55. 10.1021/acsanm.8b0177410.1021/acsanm.8b01774 ↗
56. 10.3390/molecules2305103410.3390/molecules23051034 ↗
57. 10.1021/acsomega.9b0300310.1021/acsomega.9b03003 ↗
58. 10.3390/pharmaceutics1208077210.3390/pharmaceutics12080772 ↗
59. 10.1021/acs.biomac.2c0008810.1021/acs.biomac.2c00088 ↗
60. 10.1021/acsabm.9b0085510.1021/acsabm.9b00855 ↗
61. 10.3390/pharmaceutics1506177610.3390/pharmaceutics15061776 ↗
62. 10.1021/ja307982910.1021/ja3079829 ↗
63. 10.1039/C7PY00166E10.1039/C7PY00166E ↗
64. 10.1002/smll.20200756610.1002/smll.202007566 ↗
65. 10.1021/acsami.7b1505210.1021/acsami.7b15052 ↗
66. 10.1039/C9SC05510J10.1039/C9SC05510J ↗
67. 10.1021/acs.molpharmaceut.8b0026210.1021/acs.molpharmaceut.8b00262 ↗
68. 10.1039/D3TB02765A10.1039/D3TB02765A ↗
69. 10.1039/C7SM02292A10.1039/C7SM02292A ↗
70. 10.3390/molecules2507170910.3390/molecules25071709 ↗
71. 10.1039/C4RA11455H10.1039/C4RA11455H ↗
72. 10.1021/acsmacrolett.6b0092410.1021/acsmacrolett.6b00924 ↗
73. 10.1021/acsnano.0c0959010.1021/acsnano.0c09590 ↗
74. 10.1002/cplu.20200019010.1002/cplu.202000190 ↗
75. 10.1186/s12951-021-00951-z10.1186/s12951-021-00951-z ↗
76. 10.1186/s12951-021-00990-610.1186/s12951-021-00990-6 ↗
77. 10.1021/acsmacrolett.9b0001610.1021/acsmacrolett.9b00016 ↗
78. 10.1021/acscentsci.7b0025310.1021/acscentsci.7b00253 ↗
79. 10.1021/acsnano.8b0616010.1021/acsnano.8b06160 ↗
80. 10.1021/acsmacrolett.3c0032310.1021/acsmacrolett.3c00323 ↗
81. 10.1039/D0PY00558D10.1039/D0PY00558D ↗
82. 10.1021/acs.macromol.2c0222710.1021/acs.macromol.2c02227 ↗
83. 10.1002/mabi.20140040310.1002/mabi.201400403 ↗
84. 10.1002/adfm.20110282610.1002/adfm.201102826 ↗
85. 10.1016/j.msec.2017.08.07410.1016/j.msec.2017.08.074 ↗
86. 10.1186/s12951-023-02245-y10.1186/s12951-023-02245-y ↗
87. 10.1002/adma.20210767410.1002/adma.202107674 ↗
88. 10.1021/acs.joc.6b0150910.1021/acs.joc.6b01509 ↗
89. 10.1038/s41565-022-01261-710.1038/s41565-022-01261-7 ↗
90. 10.1016/j.toxrep.2023.12.00210.1016/j.toxrep.2023.12.002 ↗
91. 10.1021/ma502062q10.1021/ma502062q ↗
92. 10.1021/jp112390d10.1021/jp112390d ↗
93. 10.1021/ma301874d10.1021/ma301874d ↗
94. 10.1039/C6PY00996D10.1039/C6PY00996D ↗
95. 10.1002/adfm.20220479110.1002/adfm.202204791 ↗
96. 10.1021/accountsmr.3c0017210.1021/accountsmr.3c00172 ↗
97. 10.1016/j.freeradbiomed.2018.10.42810.1016/j.freeradbiomed.2018.10.428 ↗
98. 10.1002/nbm.458410.1002/nbm.4584 ↗
99. 10.1016/j.ccr.2005.03.01210.1016/j.ccr.2005.03.012 ↗
100. 10.1038/s41467-023-39720-x10.1038/s41467-023-39720-x ↗